{"hands_on_practices": [{"introduction": "The journey of developing a new phage therapy begins with a crucial selection process: identifying bacteriophages that are strictly lytic. This practice challenges you to think like a phage bioinformatician, using genomic annotations to distinguish safe, therapeutic candidates from temperate phages that pose risks of lysogeny and horizontal gene transfer [@problem_id:2520361]. Mastering this rule-based classification is a fundamental skill for ensuring the safety and efficacy of any potential phage therapeutic.", "problem": "In phage therapy screening, excluding temperate bacteriophages is critical because lysogeny can mediate horizontal gene transfer and reduce bactericidal efficacy. Start from the core definitions that a temperate bacteriophage establishes lysogeny by either integrating its genome into the host chromosome via a site-specific recombinase (an integrase) and maintaining the prophage state through an immunity switch (for example, a repressor analogous to the Lambda CI repressor), or by persisting extrachromosomally with dedicated maintenance systems; in contrast, a strictly virulent bacteriophage lacks the genetic circuitry required to enter and maintain lysogeny and reproduces exclusively through the lytic cycle. Also use the general facts that homologous recombination functions (for example, RecA-like or Red-family recombinases) are widespread in both temperate and virulent bacteriophages because they support genome replication and repair, whereas site-specific integrases and prophage maintenance repressors are specifically tied to lysogeny.\n\nYou are provided a typical annotation feature set for a newly sequenced double-stranded Deoxyribonucleic Acid (DNA) bacteriophage: predicted structural and lysis genes, a set of DNA metabolism genes including at least one recombinase homolog from a homologous recombination family, and putative regulatory proteins of diverse helix-turn-helix families. You must select a general, rule-based classifier that maps genome annotations to either “temperate” or “virulent” using only the presence, absence, and synteny of the following modules: site-specific integrase, lysogeny maintenance repressor, excisionase, and short attachment-site motifs near the integration module (attP), together with the presence of generic homologous recombination genes.\n\nWhich of the following rule sets is the most biologically justified and robust for classifying an unknown phage genome as temperate versus virulent, while minimizing both false positives driven by generic recombination machinery and false negatives due to annotation divergence of lysogeny genes?\n\nA. Call a genome temperate if any homologous recombination gene (for example, RecA-like, UvsX, or RedBeta) is present; otherwise call it virulent.\n\nB. Call a genome temperate if a site-specific integrase is present, regardless of whether a lysogeny maintenance repressor, excisionase, or attP-like motif is detected; otherwise call it virulent.\n\nC. Call a genome temperate if a site-specific integrase is present and is co-localized within a syntenic lysogeny cassette that includes at least one of the following: a repressor analogous to the Lambda CI repressor (cI), an excisionase, or a recognizable attP-like attachment motif; otherwise call it virulent. Treat the presence of homologous recombination genes as non-informative for temperate status.\n\nD. Call a genome temperate if a Cro-like transcriptional regulator is present and structural lysis genes are intact; otherwise call it virulent.\n\nE. Call a genome temperate only if both a lysogeny maintenance repressor and an excisionase are present; otherwise call it virulent, regardless of integrase status.", "solution": "The task is to identify the most robust and biologically justified rule set for classifying a bacteriophage genome as temperate or virulent, based on a provided set of definitions and biological facts. The classifier must minimize both false positives and false negatives.\n\nFirst, validation of the problem statement is required.\n\n**Step 1: Extract Givens**\n- **Goal:** Classify bacteriophage genomes as \"temperate\" or \"virulent\" for phage therapy screening, where temperate phages are to be excluded.\n- **Definition of a Temperate Bacteriophage:** Establishes lysogeny by one of two mechanisms: $1$) integration of its genome into the host chromosome via a site-specific recombinase (integrase), with maintenance by an immunity switch (e.g., repressor), or $2$) persistence as an extrachromosomal element.\n- **Definition of a Strictly Virulent Bacteriophage:** Lacks the genetic machinery for lysogeny and reproduces exclusively through the lytic cycle.\n- **Key Genetic Markers:**\n    - **Homologous Recombination Genes** (e.g., `RecA`-like, `Red`-family): Widespread in *both* temperate and virulent phages for replication and repair. Not a distinguishing feature.\n    - **Site-Specific Integrases** and **Prophage Maintenance Repressors:** Specifically associated with the lysogenic cycle.\n- **Classifier Inputs:** Presence, absence, and synteny of the following modules: site-specific integrase, lysogeny maintenance repressor, excisionase, and `attP` motifs, along with generic homologous recombination genes.\n- **Classifier Performance Criteria:**\n    - Must be biologically justified and robust.\n    - Must minimize false positives (e.g., avoid classifying virulent phages as temperate based on generic recombination machinery).\n    - Must minimize false negatives (e.g., account for potential failure to annotate some lysogeny genes due to sequence divergence).\n\n**Step 2: Validate Using Extracted Givens**\nThe problem statement is scientifically grounded, well-posed, and objective. It provides clear, standard definitions from molecular biology and virology regarding bacteriophage life cycles. The distinction between site-specific recombination for lysogeny and homologous recombination for general DNA metabolism is a fundamental concept and is correctly presented. The task is a realistic scenario in bioinformatics and phage genomics. The premises are internally consistent and sufficient to evaluate the options. No scientific flaws, ambiguities, or contradictions are present.\n\n**Step 3: Verdict and Action**\nThe problem is valid. Proceed to solution.\n\n**Derivation of the Correct Answer**\n\nThe optimal classification rule must leverage the genetic markers that are specific to the temperate lifestyle while being resilient to the limitations of genome annotation.\n\n1.  **Core Marker for Integration:** The problem defines integrase-mediated lysogeny as a primary mechanism. Therefore, the presence of a **site-specific integrase** gene is the strongest single indicator of a phage's potential to be temperate.\n2.  **Addressing False Positives:** Relying solely on an integrase could be problematic. Genes can be non-functional (pseudogenes) or part of other mobile genetic elements. A more robust method would require corroborating evidence. The problem states that the genes for a specific function are often clustered. Therefore, requiring the integrase to be **syntenic** (co-localized) with other genes involved in lysogeny provides much higher confidence.\n3.  **Addressing False Negatives:** The problem explicitly mentions the risk of false negatives due to \"annotation divergence of lysogeny genes.\" This means a truly temperate phage might be missed if the classifier requires the presence of all canonical lysogeny genes (e.g., integrase, repressor, and excisionase). A robust rule should be flexible. Finding an integrase plus **at least one** other piece of evidence (e.g., a repressor, an excisionase, or a specific DNA motif like `attP`) in a syntenic block is a strategy that balances specificity with sensitivity.\n4.  **Handling Non-Informative Markers:** The problem explicitly states that homologous recombination genes are ubiquitous in both phage types. An effective rule must recognize this and treat their presence as non-informative for the temperate-vs-virulent classification to avoid a high rate of false positives.\n\n**Option-by-Option Analysis**\n\n**A. Call a genome temperate if any homologous recombination gene (for example, `RecA`-like, `UvsX`, or `RedBeta`) is present; otherwise call it virulent.**\n- **Evaluation:** This rule is fundamentally flawed. The problem states that homologous recombination genes are present in both virulent and temperate phages for functions like DNA replication and repair. Using this as a criterion for temperance would misclassify nearly every virulent phage that performs homologous recombination as temperate. This leads to an unacceptable rate of false positives.\n- **Verdict:** **Incorrect**.\n\n**B. Call a genome temperate if a site-specific integrase is present, regardless of whether a lysogeny maintenance repressor, excisionase, or `attP`-like motif is detected; otherwise call it virulent.**\n- **Evaluation:** This rule correctly identifies the most important marker, the site-specific integrase. It is a significant improvement over option A. However, it fails to use other available information to increase confidence. An isolated integrase gene could be a molecular fossil or part of a different, non-phage mobile element. The problem asks for the *most* robust rule, and this rule is less robust than one that requires additional, co-localized evidence.\n- **Verdict:** **Incorrect**.\n\n**C. Call a genome temperate if a site-specific integrase is present and is co-localized within a syntenic lysogeny cassette that includes at least one of the following: a repressor analogous to the Lambda `CI` repressor (cI), an excisionase, or a recognizable `attP`-like attachment motif; otherwise call it virulent. Treat the presence of homologous recombination genes as non-informative for temperate status.**\n- **Evaluation:** This rule is the most sophisticated and biologically sound.\n    - It uses the key marker (integrase).\n    - It uses synteny (co-localization) to confirm that the integrase is part of a functional module, reducing false positives.\n    - Its requirement for \"at least one\" of several other lysogeny markers (repressor, excisionase, `attP`) makes it robust against annotation failure, thus minimizing false negatives.\n    - It correctly identifies homologous recombination genes as non-discriminatory, preventing a major source of false positives.\n    This rule directly aligns with all principles and constraints given in the problem statement.\n- **Verdict:** **Correct**.\n\n**D. Call a genome temperate if a `Cro`-like transcriptional regulator is present and structural lysis genes are intact; otherwise call it virulent.**\n- **Evaluation:** This rule is based on a misunderstanding of phage regulatory circuits. In the canonical lambda phage model, the `Cro` protein is a key promoter of the *lytic* cycle, acting in opposition to the `CI` repressor which maintains lysogeny. Presence of `Cro` is an indicator of a switch towards lysis, not a marker for establishing or maintaining lysogeny itself. Virulent phages also have regulatory and lysis genes. This rule is biologically illogical for identifying temperate phages.\n- **Verdict:** **Incorrect**.\n\n**E. Call a genome temperate only if both a lysogeny maintenance repressor and an excisionase are present; otherwise call it virulent, regardless of integrase status.**\n- **Evaluation:** This rule is overly strict and flawed. First, by requiring *both* a repressor and an excisionase, it significantly increases the probability of false negatives if either gene is too diverged to be annotated correctly. Second, it completely ignores the integrase, which is the central enzyme for the primary mode of lysogeny described. A rule that ignores the most critical gene for the process it aims to detect is not robust.\n- **Verdict:** **Incorrect**.", "answer": "$$\\boxed{C}$$", "id": "2520361"}, {"introduction": "Once a suitable lytic phage is identified, the next step is to understand the quantitative rules governing its battle with the target bacteria. This exercise introduces a classic mathematical model of phage-bacterium population dynamics and asks you to apply the powerful technique of non-dimensionalization [@problem_id:2520281]. By distilling the system into a set of core dimensionless groups, you will uncover the fundamental parameter that predicts whether a phage population can successfully overwhelm a bacterial infection, providing deep insight into the conditions required for therapeutic success.", "problem": "A minimal mechanistic model of bacteriophage treatment against a single, well-mixed bacterial population assumes logistic bacterial growth and mass-action adsorption of phage to bacteria, with infection yielding offspring phage after lysis and free phage decaying. Let $B(t)$ denote bacterial density (in Colony Forming Units per milliliter (CFU/mL)) and $P(t)$ denote free phage density (in Plaque Forming Units per milliliter (PFU/mL)). Consider the system\n$$\n\\frac{dB}{dt} = r\\,B\\left(1-\\frac{B}{K}\\right) - \\phi\\,B\\,P,\n\\qquad\n\\frac{dP}{dt} = \\beta\\,\\phi\\,B\\,P - \\omega\\,P,\n$$\nwhere $r$ is the bacterial intrinsic growth rate (per hour), $K$ is the bacterial carrying capacity (CFU/mL), $\\phi$ is the phage adsorption rate (mL per PFU per hour), $\\beta$ is the burst size (dimensionless), and $\\omega$ is the free phage loss rate (per hour).\n\nStarting only from the definitions of mass-action infection and logistic growth, non-dimensionalize this system by introducing appropriately scaled variables for time, bacterial density, and phage density so that the resulting system is written in terms of dimensionless variables and a minimal set of independent dimensionless groups. Identify these dimensionless groups and briefly justify their biological meaning in relation to therapy success. In particular, identify the single dimensionless group that determines whether the phage population can increase when bacteria are at carrying capacity.\n\nThen, using the parameter values $r = 0.8$ h$^{-1}$, $K = 5 \\times 10^{8}$ CFU/mL, $\\phi = 3 \\times 10^{-10}$ mL/(PFU$\\cdot$h), $\\beta = 60$, and $\\omega = 0.25$ h$^{-1}$, compute the numerical value of that single dimensionless group. Round your final answer to four significant figures and express it as a pure number (dimensionless).", "solution": "The problem as stated is scientifically grounded, dimensionally consistent, and well-posed. The model is a standard representation of phage-bacterium dynamics, and the provided parameters are physically realistic. We shall therefore proceed to the solution.\n\nThe system of differential equations is given by:\n$$ \\frac{dB}{dt} = r\\,B\\left(1-\\frac{B}{K}\\right) - \\phi\\,B\\,P $$\n$$ \\frac{dP}{dt} = \\beta\\,\\phi\\,B\\,P - \\omega\\,P $$\nHere, $B$ is the bacterial density, $P$ is the phage density, and $t$ is time. The parameters $r, K, \\phi, \\beta, \\omega$ are the bacterial growth rate, carrying capacity, phage adsorption rate, burst size, and phage loss rate, respectively.\n\nTo non-dimensionalize the system, we introduce scaled variables for time, bacterial density, and phage density. The choice of scaling factors is based on characteristic scales inherent to the system.\nLet us define the dimensionless variables $\\tau$, $b(\\tau)$, and $p(\\tau)$ as follows:\n$1$. For bacterial density $B$, the natural scale is the carrying capacity $K$. We set $B = K b$. Thus, $b = B/K$ is the bacterial density as a fraction of its maximum capacity, with $0 \\le b \\le 1$.\n$2$. For time $t$, a characteristic timescale is the inverse of the bacterial intrinsic growth rate, $1/r$. We set $t = \\tau/r$, so $\\tau = r t$. This measures time in units of bacterial generation time.\n$3$. For phage density $P$, the scaling is not immediately obvious. We introduce a characteristic phage density $P_c$ and set $P = P_c p$. The value of $P_c$ will be chosen to simplify the resulting dimensionless equations.\n\nWe now perform a change of variables in the differential equations.\nUsing the chain rule, the time derivatives become:\n$$ \\frac{d}{dt} = \\frac{d\\tau}{dt} \\frac{d}{d\\tau} = r \\frac{d}{d\\tau} $$\nSubstituting the scaled variables into the first equation for bacteria:\n$$ \\frac{d(Kb)}{dt} = r \\frac{d(Kb)}{d\\tau} = K r \\frac{db}{d\\tau} $$\nThe right-hand side becomes:\n$$ r(Kb)\\left(1-\\frac{Kb}{K}\\right) - \\phi(Kb)(P_c p) = r K b(1-b) - \\phi K P_c b p $$\nEquating the two gives:\n$$ K r \\frac{db}{d\\tau} = r K b(1-b) - \\phi K P_c b p $$\nDividing the entire equation by $K r$:\n$$ \\frac{db}{d\\tau} = b(1-b) - \\frac{\\phi P_c}{r} b p $$\nNow, for the second equation for phages:\n$$ \\frac{d(P_c p)}{dt} = r \\frac{d(P_c p)}{d\\tau} = P_c r \\frac{dp}{d\\tau} $$\nThe right-hand side becomes:\n$$ \\beta \\phi (Kb) (P_c p) - \\omega (P_c p) = \\beta \\phi K P_c b p - \\omega P_c p $$\nEquating the two gives:\n$$ P_c r \\frac{dp}{d\\tau} = \\beta \\phi K P_c b p - \\omega P_c p $$\nDividing by $P_c r$ (assuming $P_c \\ne 0, r \\ne 0$):\n$$ \\frac{dp}{d\\tau} = \\left(\\frac{\\beta \\phi K}{r}\\right) b p - \\left(\\frac{\\omega}{r}\\right) p = p \\left[ \\left(\\frac{\\beta \\phi K}{r}\\right) b - \\left(\\frac{\\omega}{r}\\right) \\right] $$\nTo achieve a minimal form, we must choose the scaling factor $P_c$. In the equation for $db/d\\tau$, the dimensionless coefficient is $\\frac{\\phi P_c}{r}$. The most natural choice\nis to set this coefficient to unity:\n$$ \\frac{\\phi P_c}{r} = 1 \\implies P_c = \\frac{r}{\\phi} $$\nThis choice defines the characteristic phage density $P_c$ in terms of the system parameters.\n\nWith this choice of $P_c$, the non-dimensionalized system is:\n$$ \\frac{db}{d\\tau} = b(1-b) - b p $$\n$$ \\frac{dp}{d\\tau} = p \\left[ \\left( \\frac{\\beta \\phi K}{r} \\right) b - \\left( \\frac{\\omega}{r} \\right) \\right] $$\nThis system is described by two independent dimensionless groups:\n$$ \\Pi_1 = \\frac{\\beta \\phi K}{r} \\quad \\text{and} \\quad \\Pi_2 = \\frac{\\omega}{r} $$\nThe biological meaning of these groups is as follows:\n- $\\Pi_2 = \\omega/r$: This is the ratio of the phage loss rate $\\omega$ to the bacterial intrinsic growth rate $r$. It compares the timescale of phage persistence ($1/\\omega$) to the timescale of bacterial reproduction ($1/r$). A large $\\Pi_2$ signifies that phages are cleared much faster than bacteria can grow, presenting a challenge for therapy.\n- $\\Pi_1 = (\\beta \\phi K)/r$: This group is the ratio of the maximum phage production rate per phage (at $B=K$) to the bacterial growth rate. The term $\\phi K$ is the maximum adsorption rate for a single phage (units of $h^{-1}$), and $\\beta \\phi K$ is thus the maximum rate of new phage generation per phage. $\\Pi_1$ therefore represents the phage's maximal reproductive potential relative to the host's intrinsic growth potential.\n\nNext, we identify the single dimensionless group that determines whether the phage population can increase when bacteria are at carrying capacity. This condition corresponds to examining the sign of $dP/dt$ when $B=K$. From the original dimensional equation:\n$$ \\frac{dP}{dt} = P(\\beta \\phi B - \\omega) $$\nFor the phage population to increase, we require $dP/dt > 0$. Since $P>0$, this simplifies to:\n$$ \\beta \\phi B - \\omega > 0 $$\nWhen the bacterial population is at its carrying capacity, $B=K$, this condition becomes:\n$$ \\beta \\phi K - \\omega > 0 \\implies \\beta \\phi K > \\omega $$\nThis inequality can be expressed in terms of a single dimensionless group by dividing by $\\omega$:\n$$ R_p \\equiv \\frac{\\beta \\phi K}{\\omega} > 1 $$\nThis group, $R_p$, is the single parameter in question. It is often termed the basic reproductive number of the phage in this context. It represents the average number of new infectious phage progeny produced by a single phage in a susceptible bacterial population at carrying capacity, over the lifetime of the phage ($1/\\omega$). If $R_p > 1$, each phage more than replaces itself, and the phage population grows. If $R_p < 1$, the phage population will decline towards extinction. Note that $R_p = \\Pi_1 / \\Pi_2$.\n\nFinally, we compute the numerical value of this dimensionless group using the provided parameters:\n$r = 0.8$ h$^{-1}$\n$K = 5 \\times 10^{8}$ CFU/mL\n$\\phi = 3 \\times 10^{-10}$ mL/(PFU$\\cdot$h)\n$\\beta = 60$\n$\\omega = 0.25$ h$^{-1}$\n\nSubstituting these values into the expression for $R_p$:\n$$ R_p = \\frac{\\beta \\phi K}{\\omega} = \\frac{60 \\times (3 \\times 10^{-10}) \\times (5 \\times 10^{8})}{0.25} $$\nFirst, calculate the numerator:\n$$ \\beta \\phi K = 60 \\times (3 \\times 10^{-10}) \\times (5 \\times 10^{8}) = (60 \\times 3 \\times 5) \\times 10^{-10+8} = 900 \\times 10^{-2} = 9 $$\nNow, divide by the denominator:\n$$ R_p = \\frac{9}{0.25} = \\frac{9}{1/4} = 9 \\times 4 = 36 $$\nThe numerical value is exactly $36$. The problem requires the answer to be rounded to four significant figures, which is $36.00$.", "answer": "$$\n\\boxed{36.00}\n$$", "id": "2520281"}, {"introduction": "A potent phage is only effective if it reaches the patient in a viable state. This final practice bridges the gap between production and clinical administration, focusing on the critical issue of pharmaceutical stability [@problem_id:2520295]. By modeling the first-order decay of a phage formulation during storage, you will determine its practical shelf life, ensuring that the dose administered still meets the minimum multiplicity of infection (MOI) required for a therapeutic effect.", "problem": "A hospital pharmacy prepares a monovalent lytic bacteriophage formulation for Pseudomonas aeruginosa. The active virions degrade during refrigerated storage and the viable titer decays according to first-order kinetics, modeled as $P(t)=P_{0}\\exp(-k t)$, where $P(t)$ is the viable titer in plaque-forming units per milliliter (PFU mL$^{-1}$) at storage time $t$ in days, $P_{0}$ is the initial viable titer, and $k$ is the first-order rate constant. The product is used for a single-dose intraluminal instillation in which a fixed volume of the stored product is prepared and administered as follows.\n\nA single dose is prepared by taking $v_{p}$ milliliters of the stored product and diluting it $1{:}4$ with sterile buffer; the entire prepared volume is instilled. Only the phage present in the $v_{p}$ milliliters of product contributes virions; the buffer contains no phage. Due to adsorption to preparation surfaces and loss during delivery, a net fraction $f$ of the virions present in the administered fluid arrives intact at the infection site. The clinical protocol requires that the initial Multiplicity of Infection (MOI), defined as the ratio of virions at the site to bacterial cells at the time of administration, be at least a specified minimum to ensure rapid lysis. The site has a bacterial burden of $N_{b}$ in colony-forming units (CFU), and the minimum required MOI is $\\mathrm{MOI}_{\\min}$.\n\nAssume the following parameter values, all scientifically plausible and self-consistent for a refrigerated formulation:\n- Initial titer $P_{0}=2.0\\times 10^{10}$ PFU mL$^{-1}$.\n- First-order decay rate constant $k=4.50\\times 10^{-3}$ day$^{-1}$.\n- Volume of product used per dose $v_{p}=4.0$ mL.\n- Net delivery fraction $f=0.30$.\n- Bacterial burden at the site $N_{b}=5.0\\times 10^{8}$ CFU.\n- Minimum required MOI $\\mathrm{MOI}_{\\min}=10$.\n\nStarting from the definitions above and fundamental first-order kinetics, determine the latest storage time $t^{\\ast}$ (shelf life) after manufacture for which a single prepared dose still just meets the minimum effective dose requirement at the moment of administration. Express your answer in days. Round your answer to three significant figures. Do not include units in your final boxed answer.", "solution": "The problem requires the determination of the maximum storage time, or shelf life, $t^{\\ast}$, for a bacteriophage formulation, after which it no longer meets the minimum required therapeutic efficacy. The validation of the problem statement confirms that it is scientifically grounded, well-posed, and contains all necessary and consistent information to proceed with a quantitative solution.\n\nThe fundamental principle is the first-order decay of the viable phage titer, $P(t)$, over time $t$, which is given by the equation:\n$$P(t) = P_{0}\\exp(-k t)$$\nwhere $P(t)$ is the titer in PFU mL$^{-1}$ at time $t$ in days, $P_{0}$ is the initial titer, and $k$ is the decay rate constant.\n\nThe process to determine the shelf life $t^{\\ast}$ involves several steps.\n\nFirst, we calculate the total number of viable virions, $N_{p, \\text{dose}}(t)$, contained in the volume $v_{p}$ of product used to prepare a single dose at a given storage time $t$. This is the product of the titer at that time and the volume taken:\n$$N_{p, \\text{dose}}(t) = P(t) \\cdot v_{p}$$\nSubstituting the expression for $P(t)$:\n$$N_{p, \\text{dose}}(t) = P_{0}v_{p}\\exp(-k t)$$\nIt is specified that a dilution step follows, but a crucial clarification is provided: \"Only the phage present in the $v_{p}$ milliliters of product contributes virions,\" and this volume is what is administered after dilution. Therefore, the dilution ratio does not alter the total number of virions in the dose, only their concentration in the final instilled volume.\n\nSecond, we account for the loss of virions during administration. A net fraction $f$ of the administered virions reaches the infection site. The number of virions arriving at the site, $N_{v, \\text{site}}(t)$, is therefore:\n$$N_{v, \\text{site}}(t) = f \\cdot N_{p, \\text{dose}}(t) = f P_{0} v_{p} \\exp(-k t)$$\n\nThird, we use the definition of the Multiplicity of Infection (MOI), which is the ratio of virions at the site to the number of bacterial cells, $N_{b}$. The MOI at the time of administration, as a function of storage time $t$, is:\n$$\\mathrm{MOI}(t) = \\frac{N_{v, \\text{site}}(t)}{N_{b}}$$\nSubstituting the expression for $N_{v, \\text{site}}(t)$:\n$$\\mathrm{MOI}(t) = \\frac{f P_{0} v_{p} \\exp(-k t)}{N_{b}}$$\n\nThe clinical protocol requires that the MOI must be at least a minimum value, $\\mathrm{MOI}_{\\min}$. The shelf life $t^{\\ast}$ is the latest time at which this condition is just met. Thus, we set $\\mathrm{MOI}(t^{\\ast})$ equal to $\\mathrm{MOI}_{\\min}$:\n$$\\frac{f P_{0} v_{p} \\exp(-k t^{\\ast})}{N_{b}} = \\mathrm{MOI}_{\\min}$$\n\nNow, we must solve this equation for $t^{\\ast}$. We begin by isolating the exponential term:\n$$\\exp(-k t^{\\ast}) = \\frac{\\mathrm{MOI}_{\\min} N_{b}}{f P_{0} v_{p}}$$\nNext, we take the natural logarithm of both sides of the equation:\n$$\\ln(\\exp(-k t^{\\ast})) = \\ln\\left(\\frac{\\mathrm{MOI}_{\\min} N_{b}}{f P_{0} v_{p}}\\right)$$\n$$-k t^{\\ast} = \\ln\\left(\\frac{\\mathrm{MOI}_{\\min} N_{b}}{f P_{0} v_{p}}\\right)$$\nFinally, we solve for $t^{\\ast}$. Using the logarithmic identity $\\ln(A/B) = -\\ln(B/A)$, we can write the expression in a more intuitive form:\n$$t^{\\ast} = -\\frac{1}{k} \\ln\\left(\\frac{\\mathrm{MOI}_{\\min} N_{b}}{f P_{0} v_{p}}\\right) = \\frac{1}{k} \\ln\\left(\\frac{f P_{0} v_{p}}{\\mathrm{MOI}_{\\min} N_{b}}\\right)$$\nThis is the symbolic solution for the shelf life.\n\nWe now substitute the provided numerical values:\n- $P_{0} = 2.0 \\times 10^{10}$ PFU mL$^{-1}$\n- $k = 4.50 \\times 10^{-3}$ day$^{-1}$\n- $v_{p} = 4.0$ mL\n- $f = 0.30$\n- $N_{b} = 5.0 \\times 10^{8}$ CFU\n- $\\mathrm{MOI}_{\\min} = 10$\n\nWe calculate the argument of the natural logarithm:\n$$\\frac{f P_{0} v_{p}}{\\mathrm{MOI}_{\\min} N_{b}} = \\frac{(0.30) \\cdot (2.0 \\times 10^{10}) \\cdot (4.0)}{(10) \\cdot (5.0 \\times 10^{8})} = \\frac{2.4 \\times 10^{10}}{5.0 \\times 10^{9}} = 4.8$$\nNow, substitute this value into the expression for $t^{\\ast}$:\n$$t^{\\ast} = \\frac{1}{4.50 \\times 10^{-3}} \\ln(4.8)$$\nUsing a calculator for the natural logarithm:\n$$\\ln(4.8) \\approx 1.5686159$$\n$$t^{\\ast} \\approx \\frac{1.5686159}{4.50 \\times 10^{-3}} \\approx 348.5813 \\text{ days}$$\nThe problem requires the answer to be rounded to three significant figures. The calculated value is $348.5813...$. The fourth significant digit is $5$, which requires rounding up the third digit.\n$$t^{\\ast} \\approx 349 \\text{ days}$$\nThus, the maximum storage time for the formulation to remain effective according to the specified protocol is $349$ days.", "answer": "$$\\boxed{349}$$", "id": "2520295"}]}